CD33-CD123-CLL1 CART-T cell therapy - Hebei Taihe Chunyu Biotechnology
Alternative Names: CD33xCD123xCLL1 CAR-T cell therapy - Hebei Taihe Chunyu BiotechnologyLatest Information Update: 02 May 2025
At a glance
- Originator Hebei Taihe Chunyu Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 08 Apr 2025 Preclinical trials in Haematological malignancies in China (Parenteral)
- 08 Apr 2025 ebei Taihe Chunyu Biotechnology plans a phase I/II trial for Haematological malignancies (Second-line therapy or greater) in China (NCT06917105)